

Tabel 6: Samenvatting relevantste literatuur

Schema	Referentie	Type studie	Mediane Follow-up	n=	ORR (%)	Major response (%)	(Mediane)PFS
Ibrutinib 420 mg, Rituximab R*	Dimopoulos 2017 ⁷⁵	Prospective	18.1 mnd	31	90	71	18-mnd: 82%
R-Ibrutinib	Dimopoulos 2018 ⁷³	Prospective	26.5 mnd	75 (41 rec)	92**	72**	30 mnd: 80%
Ibrutinib 420 mg	Treon 2015 ⁷⁵	Prospective	Not reported	63	90.5	73	24 mnd: 69.1% 5 jr: 54%
Acalabrutinib 2 dd 100 mg	Owen 2020 ⁸⁸	Prospective	27.4 mnd	92	93	78	24 mnd; 82%
Zanubrutinib	An et al 2021 ⁹⁶	Prospective	33 mnd	44	76	70	61% na 24 mnd
Zanubrutinib	Trotman et al 2020 ⁹⁷	Prospective	36 mnd	77	96	82	80% na 3 jaar
Zanubrutinib	Tam et al 2020 ⁹⁸	Prospective	18 mnd	102	94	77	85% na 18 mnd
Zanubrutinib *alleen MYD88WT	Dimopoulos 2020 ⁹⁹	Prospective	18	28	81	50	68% na 18 mnd
Rituximab 4x	Dimopoulos 2018 ⁷³	prospective	26.5 mnd	41	47**	32	30 mnd: 22%
Benda ± R ± Ofa	Treon 2011 ⁷⁷	retrospective	7.5 mnd	30 (54% refr)	79	79	13.2 mnd
R-Benda	Paludo 2018 ⁶⁵	retrospective	32 mnd	44	95	81	58 mnd
R-Benda	Tedeschi 2015 ⁷⁸	retrospective	19 mnd	71 (14 R*)	80.2	74.6	Not reported
DRC	Paludo 2017 ⁶¹	retrospective	51 mnd	50 (40% refr)	87	68	32 mnd

CAP	Leblond 2001 ⁸²	prospective	52 mnd	45	NR	11	8 mnd (est)
R-bortezomib	Ghobrial 2010 ⁶⁸	prospective	16 mnd	37	81	51	15.6 mnd
Bortezomib	Treon 2007 ⁸⁰	prospective	18.2 mnd	27	85	48.1	6.6 mnd
Bortezomib	Chen 2007 ⁸¹	prospective	Not reported	27	78	44	16.3 mnd
Bort-dex	Leblond 2017	prospective	42.5 mnd	34	75	43	15.3 mnd
R-ixazomib-dex	Amaador 2021 ⁸⁷	Prospective	24 mnd	60	88	68	
OFC	Gavriatopoulou 2017 ⁸⁶	prospective	23 mnd	12	92	84	23 mnd; 75%
R-2CDA	Laszlo 2010 ⁸³	prospective	50 mnd	29	89.6	79	60.3 mnd (est)
Fludarabine	Leblond 2001 ⁸²	prospective	52 mnd	45	NR	14	8 mnd (est)
FCR	Souchet 2016 ⁸⁵	retrospectief	47 mnd	82	85.4	76.8	48 mnd: 67%
FCR	Tedeschi 2013 ⁸⁴	retrospectief	51 mnd	40	80	80	77 mnd
Venetoclax	Castillo 2021	Prospectief	33 maanden	32	84	81	30